Novel approaches to treatment of advanced colorectal cancer with anti‐EGFR monoclonal antibodies-Reference-Cited by-同舟云学术

Novel approaches to treatment of advanced colorectal cancer with anti‐EGFR monoclonal antibodies

Published:2006-01 Issue:8 Volume:38 Page:545-551
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Zhang Wu¹,Gordon Michael¹,Lenz Heinz‐Josef¹²

Affiliation:

1. Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California

2. Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546630601070812

Reference44 articles.

1. Cancer Statistics, 2006

2. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

3. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

4. Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986

5. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-throughput computational screening and <i>in vitro</i> evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR—HER2 dual inhibitor in gastric tumors;Oncology Research;2024

2. Targeting Angiogenesis for Colorectal Cancer Therapy;Colon Cancer Diagnosis and Therapy;2021

3. Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment;Advanced Therapeutics;2020-08-31

4. The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance;PLOS ONE;2016-09-22

5. Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy;Journal of Clinical Pathology;2016-04-22